- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim, Germany, August 28, 2019 – In August, Bayer Animal Health launched Drontal™ Plus Tasty in China. The product is an upgrade of Drontal™ Plus Flavor and offers new innovative key features.
Drontal is one of the most widely used worm treatment products in the world with a proven efficacy against all relevant gastrointestinal worms and has been recommended by veterinarians for 30 years. 10 years ago Drontal was launched in China in the veterinary channel and has been very successful ever since.
“Drontal™ is a premium brand in China with a leading position in the deworming market,” explains Bin Liu, Head of the Companion Animal Business at Bayer Animal Health China. “With Drontal™ Plus Tasty we offer veterinarians and pet owners an innovative improvement of the original Drontal. Its new key features include an improved palatability with a tasty formulation and an attractive bone shape.”
Especially in mega-cities like Shanghai or Beijing, the interest in companion animals has risen significantly over the past years. With the growing number of pets, owners have become more aware that parasite protection is vital to ensure the health of a pet, and ultimately, that of the family. “Endo products against internal parasites, such as worms, represent about 20% of the Companion Animal parasiticide market,” says Christoph Vetten, Head of Greater China for Bayer Animal Health. “This market is very important for us and we see significant growth potential here.”
Drontal™ Plus Tasty will be available in both channels, the veterinary channel and on e-Commerce platforms. “With the new product, we will strengthen our leadership in endoparasiticides for dogs, e.g. by further exploiting the opportunities that e-Commerce channels can offer,” explains Vetten. “Of course, the veterinary channel remains very important to us, as many dog owners treat reactively against worms after the veterinarian advises them to do so.”
“With the improved taste and bone shape, Drontal™ Plus Tasty offers a real benefit for dogs and owners, because it is easy to administer,” adds Bin Liu. “To support our business partners, we will significantly increase the brand awareness for Drontal™ Plus Tasty among dog owners with a digital communication campaign.”
This week the enhanced Drontal™ Plus Tasty was presented to 150 key veterinary costumers during a launch event in Nanjing. “The interest was huge, and the new features have been received very positively,” said Bin Liu.
To find out more please see: http://www.drontal.com.
About Drontal™ Plus Tasty
Drontal is a dewormer that kills gastrointestinal worms found in dogs and cats. It is considered as an “Endo product” (against internal parasites) with a broad spectrum that covers four different types of worms (roundworms, hookworms, whipworms tapeworms). Drontal is an effective treatment which is recommended by companion animal experts and should be repeated at least every 3 months. It is registered in over 100 countries and over 270 million pets have been treated with Drontal worldwide.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.